Published in Clin Ther on October 01, 2001
Genomics and drug response. N Engl J Med (2011) 4.35
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet (2009) 4.11
Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci U S A (2004) 2.15
Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin Pharmacol Ther (2012) 1.88
The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS (2008) 1.59
Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. Eur J Clin Microbiol Infect Dis (2004) 1.21
High rate of loss to clinical follow up among African HIV-infected patients attending a London clinic: a retrospective analysis of a clinical cohort. J Int AIDS Soc (2010) 1.21
Genetic factors in the predisposition to drug-induced hypersensitivity reactions. AAPS J (2006) 1.11
Hypersensitivity reactions to HIV therapy. Br J Clin Pharmacol (2011) 1.09
Pharmacogenetics of drug hypersensitivity. Pharmacogenomics (2010) 1.09
A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study. AIDS Res Hum Retroviruses (2012) 1.03
Pharmacogenomics and drug development. Pharmacogenomics (2005) 0.95
Antiretroviral therapy: current drugs. Infect Dis Clin North Am (2014) 0.94
Promises and challenges of pharmacogenetics: an overview of study design, methodological and statistical issues. JRSM Cardiovasc Dis (2012) 0.93
HIV-Antiretroviral Therapy Induced Liver, Gastrointestinal, and Pancreatic Injury. Int J Hepatol (2012) 0.93
Abacavir pharmacogenetics--from initial reports to standard of care. Pharmacotherapy (2013) 0.92
Critical illness in HIV-infected patients in the era of combination antiretroviral therapy. Proc Am Thorac Soc (2011) 0.92
Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in ART-naïve ACTG clinical trials participants. Pac Symp Biocomput (2011) 0.91
HLA associations and clinical implications in T-cell mediated drug hypersensitivity reactions: an updated review. J Immunol Res (2014) 0.91
HLA-B*5701 testing to predict abacavir hypersensitivity. PLoS Curr (2010) 0.89
The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future. Br J Clin Pharmacol (2015) 0.88
Cardiac biomarkers in HIV-exposed uninfected children. AIDS (2013) 0.88
The Pharmacogenomic HLA Biomarker Associated to Adverse Abacavir Reactions: Comparative Analysis of Different Genotyping Methods. Curr Genomics (2012) 0.87
Pharmacogenetic testing: Current Evidence of Clinical Utility. Ther Adv Drug Saf (2013) 0.87
Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. Eur J Clin Pharmacol (2010) 0.86
Severe myositis on commencement of efavirenz, abacavir and lamivudine, in the absence of lactic acidosis or classical abacavir hypersensitivity. BMJ Case Rep (2009) 0.84
Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 Infection. P T (2015) 0.84
Prevalence of human leukocyte antigen-B*5701 among HIV-infected children in Thailand and Cambodia: implications for abacavir use. Pediatr Infect Dis J (2013) 0.83
Translational research in infectious disease: current paradigms and challenges ahead. Transl Res (2012) 0.83
Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany. Eur J Med Res (2010) 0.83
Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment. BMC Infect Dis (2005) 0.80
Direct PCR: a new pharmacogenetic approach for the inexpensive testing of HLA-B*57:01. Pharmacogenomics J (2014) 0.80
The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions. Immunogenetics (2017) 0.80
The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity. Int J Mol Sci (2016) 0.79
Abacavir/lamivudine combination in the treatment of HIV: a review. Ther Clin Risk Manag (2010) 0.79
Critical care of persons infected with the human immunodeficiency virus. Clin Chest Med (2013) 0.79
Antiretroviral Therapy-associated Serious and Life-threatening Toxicities. Curr Infect Dis Rep (2003) 0.78
Comparison of methods for in-house screening of HLA-B*57:01 to prevent abacavir hypersensitivity in HIV-1 care. PLoS One (2015) 0.77
Pharmacology: A false sense of non-self. Nature (2012) 0.77
Relaxation effect of abacavir on rat basilar arteries. PLoS One (2015) 0.77
Genetic Markers of the Host in Persons Living with HTLV-1, HIV and HCV Infections. Viruses (2016) 0.76
Adversomics: a new paradigm for vaccine safety and design. Expert Rev Vaccines (2015) 0.76
Frequency of HLA B*5701 allele carriers in abacavir treated-HIV infected patients and controls from northeastern Brazil. Clinics (Sao Paulo) (2011) 0.76
Cutaneous drug hypersensitivity: immunological and genetic perspective. Indian J Dermatol (2011) 0.75
Pharmacogenetics as a tool to tailor antiretroviral therapy: A review. World J Virol (2015) 0.75
A Prospective Screening of HLA-B*57.01 Allelic Variant for Preventing the Hypersensivity Reaction to Abacavir: Experience from the Laboratory of Molecular Biology of the Infectious Diseases Division at the University Hospital of Salerno. Transl Med UniSa (2014) 0.75
Prevalence of HLA-B*5701 and Its Relationship with Abacavir Hypersensitivity Reaction in Iranian HIV-Infected Patients. Tanaffos (2016) 0.75
MinION: A Novel Tool for Predicting Drug Hypersensitivity? Front Pharmacol (2016) 0.75
Safety and Efficacy of Ziagen (Abacavir Sulfate) in HIV-Infected Korean Patients. Infect Chemother (2017) 0.75
Should abacavir be a first-line alternative for adults with HIV in sub-Saharan Africa? J Acquir Immune Defic Syndr (2017) 0.75
A polypeptide from tomato leaves induces wound-inducible proteinase inhibitor proteins. Science (1991) 9.18
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet (2009) 7.96
Geometric diffusions as a tool for harmonic analysis and structure definition of data: diffusion maps. Proc Natl Acad Sci U S A (2005) 6.24
Prescriber profile and post-marketing surveillance. Lancet (1993) 6.10
Structure, expression, and antisense inhibition of the systemin precursor gene. Science (1992) 4.43
Isolation and characterization of the proteinase inhibitor-inducing factor from tomato leaves. Identity and activity of poly- and oligogalacturonide fragments. J Biol Chem (1984) 4.02
Proteinase inhibitor-inducing factor activity in tomato leaves resides in oligosaccharides enzymically released from cell walls. Proc Natl Acad Sci U S A (1981) 3.90
Wound-induced proteinase inhibitors from tomato leaves. I. The cDNA-deduced primary structure of pre-inhibitor I and its post-translational processing. J Biol Chem (1985) 3.66
Wound-induced proteinase inhibitors from tomato leaves. II. The cDNA-deduced primary structure of pre-inhibitor II. J Biol Chem (1985) 3.44
Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. JAMA (2001) 3.28
Geometric diffusions as a tool for harmonic analysis and structure definition of data: multiscale methods. Proc Natl Acad Sci U S A (2005) 3.00
A sycamore cell wall polysaccharide and a chemically related tomato leaf polysaccharide possess similar proteinase inhibitor-inducing activities. Plant Physiol (1981) 2.64
In vitro phosphorylation of plant plasma membrane proteins in response to the proteinase inhibitor inducing factor. Proc Natl Acad Sci U S A (1989) 2.44
Molecular characterization and phylogenetic studies of a wound-inducible proteinase inhibitor I gene in Lycopersicon species. Proc Natl Acad Sci U S A (1986) 2.37
Overexpression of the prosystemin gene in transgenic tomato plants generates a systemic signal that constitutively induces proteinase inhibitor synthesis. Proc Natl Acad Sci U S A (1994) 2.31
Moderate exercise during growth in prepubertal boys: changes in bone mass, size, volumetric density, and bone strength: a controlled prospective study. J Bone Miner Res (1998) 1.88
Exercise before puberty may confer residual benefits in bone density in adulthood: studies in active prepubertal and retired female gymnasts. J Bone Miner Res (1998) 1.77
Is aggressive heparinization necessary for elective PTCA? Cathet Cardiovasc Diagn (1993) 1.43
Short stature and delayed puberty in gymnasts: influence of selection bias on leg length and the duration of training on trunk length. J Pediatr (2000) 1.41
A new monoclonal antibody to epithelial membrane antigen (EMA)-E29. A comparison of its immunocytochemical reactivity with polyclonal anti-EMA antibodies and with another monoclonal antibody, HMFG-2. Br J Cancer (1985) 1.39
Nucleotide cDNA and complete deduced amino acid sequence of a Trypanosoma cruzi ribosomal P protein (P-JL5). Nucleic Acids Res (1990) 1.38
Isolation of signaling mutants of tomato (Lycopersicon esculentum). Mol Gen Genet (1993) 1.35
Systemin: a polypeptide signal for plant defensive genes. Annu Rev Cell Dev Biol (1998) 1.35
The safety of finasteride used in benign prostatic hypertrophy: a non-interventional observational cohort study in 14,772 patients. Br J Urol (1996) 1.33
HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. AIDS (2000) 1.29
Isolation and characterization of proteinase inhibitor I from etiolated tobacco leaves. Arch Biochem Biophys (1984) 1.24
The differing tempo of growth in bone size, mass, and density in girls is region-specific. J Clin Invest (1999) 1.21
Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? HIV Med (2009) 1.20
The use of newly marketed drugs in children and adolescents prescribed in general practice. Pharmacoepidemiol Drug Saf (1999) 1.19
Regulation of synthesis of proteinase inhibitors I and II mRNAs in leaves of wounded tomato plants. Planta (1986) 1.19
Comparison of skin prick tests with specific serum immunoglobulin E in the diagnosis of fungal sensitization in patients with severe asthma. Clin Exp Allergy (2009) 1.18
Polypeptide hormones. Plant Physiol (2001) 1.13
Isolation and characterization from potato tubers of two polypeptide inhibitors of serine proteinases. Arch Biochem Biophys (1982) 1.12
The 70-kDa heat-shock protein is a major antigenic determinant in human Trypanosoma cruzi/Leishmania braziliensis braziliensis mixed infection. Immunol Lett (1992) 1.11
Safety of fluconazole in the treatment of vaginal candidiasis. A prescription-event monitoring study, with special reference to the outcome of pregnancy. Eur J Clin Pharmacol (1994) 1.08
Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase. AIDS (2000) 1.07
Allergy to laboratory animals: a prospective and cross-sectional study. J Occup Med (1989) 1.06
Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients. J Clin Epidemiol (1996) 1.06
Prognostic importance of DNA flow cytometry in non-Hodgkin's lymphomas. J Clin Pathol (1986) 1.06
Rajagopalan KV, Handler P: Purification and properties of inosinic acid dehydrogenase from Escherichia coli. J Biol Chem (1969) 1.05
Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group. J Infect Dis (1996) 1.05
Phenobarbital-induced alterations in phosphatidylcholine and triglyceride synthesis in hepatic endoplasmic reticulum. J Lipid Res (1971) 1.04
Excess mortality, length of stay and cost attributable to candidaemia. J Infect (2009) 1.04
Combined effects of laser irradiation and chemical inhibitors on the dissolution of dental enamel. Caries Res (1992) 1.02
Extraskeletal myxoid chondrosarcoma: a histochemical and immunohistochemical study. Histopathology (1986) 1.01
The high oleate trait in the cultivated peanut [Arachis hypogaea L.]. I. Isolation and characterization of two genes encoding microsomal oleoyl-PC desaturases. Mol Gen Genet (2000) 1.01
High-oleate peanut mutants result from a MITE insertion into the FAD2 gene. Theor Appl Genet (2004) 1.00
Wound complications following pre-operative radiotherapy for soft tissue sarcoma. Eur J Surg Oncol (2002) 0.97
The high oleate trait in the cultivated peanut [Arachis hypogaea L]. II. Molecular basis and genetics of the trait. Mol Gen Genet (2000) 0.96
The quality of a simulation examination using a high-fidelity child manikin. Med Educ (2003) 0.96
Recombinant Trypanosoma cruzi antigens and Chagas' disease diagnosis: analysis of a workshop. FEMS Microbiol Immunol (1991) 0.95
Doping and supplementation: the attitudes of talented young athletes. Scand J Med Sci Sports (2010) 0.94
Donor leg morbidity after pedicled rectus femoris muscle flap transfer for abdominal wall and pelvic reconstruction. Ann Plast Surg (1994) 0.93
Fibrodysplasia ossificans progressiva. AJR Am J Roentgenol (1982) 0.93
Prevalence of anti-R-13 antibodies in human Trypanosoma cruzi infection. FEMS Immunol Med Microbiol (1995) 0.93
Interactions in a host plant-virus-vector-parasitoid system: modelling the consequences for virus transmission and disease dynamics. Virus Res (2011) 0.91
Myocardial protection during cardiac operations. Decreased morbidity and lower cost with blood cardioplegia and coronary sinus perfusion. J Thorac Cardiovasc Surg (1992) 0.90
Homozygous hereditary C1q deficiency and systemic lupus erythematosus. A new family and the molecular basis of C1q deficiency in three families. Arthritis Rheum (1996) 0.89
Thallium-201 scintigraphy--a predictor of tumour necrosis in soft tissue sarcoma following preoperative radiotherapy? Eur J Surg Oncol (2003) 0.88
Critical path analysis in head and neck cancer: a management technique for surgical oncology. Eur J Oncol Nurs (2002) 0.88
Present and future of osteoporosis therapy. Bone (1995) 0.87
Enzyme specificity as a factor in regulation of fatty acid chain length in Escherichia coli. Science (1970) 0.87
Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients. AIDS (1996) 0.86
Role of the helper component in vector-specific transmission of potyviruses. J Gen Virol (1998) 0.86
Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults. Antivir Ther (2001) 0.86
Association of cytomegalovirus infection with post-transplantation cardiac rejection as studied using the polymerase chain reaction. J Med Virol (1994) 0.86
Preoperative radiotherapy for soft tissue sarcoma: the Peter MacCallum Cancer Centre experience. Eur J Surg Oncol (2006) 0.86
In vivo caries-like lesion prevention with argon laser: pilot study. J Clin Laser Med Surg (1999) 0.86
Pigmented neuroectodermal tumour of infancy: an immunohistochemical study. Histopathology (1988) 0.85
Oligouronide signaling of proteinase inhibitor genes in plants: structure-activity relationships of Di- and trigalacturonic acids and their derivatives. Arch Biochem Biophys (1992) 0.85
Disability in an urban black community in Zimbabwe. Disabil Rehabil (2002) 0.84
Safety profile of nicorandil--prescription-event monitoring (PEM) study. Pharmacoepidemiol Drug Saf (1999) 0.84
Parathyroid hormone-related protein in human term placenta and membranes. J Endocrinol (1994) 0.84
Level of medical care required for mass gatherings: the XV Winter Olympic Games in Calgary, Canada. Ann Emerg Med (1991) 0.83
DNA flow cytometry of histological material from human gastric cancer. J Pathol (1986) 0.83
Increased spinal monoamine concentrations after chronic thoracic dorsal rhizotomy in goats. J Appl Physiol (1985) (2000) 0.83
Application of DL-beta-aminobutyric acid (BABA) as a root drench to legumes inhibits the growth and reproduction of the pea aphid Acyrthosiphon pisum (Hemiptera: Aphididae). Bull Entomol Res (2005) 0.83
A simple Trypanosoma cruzi enzyme-linked immunoassay for control of human infection in nonendemic areas. FEMS Immunol Med Microbiol (1997) 0.82
The pharmacovigilance of tamsulosin: event data on 12484 patients. BJU Int (2000) 0.82
The abacavir hypersensitivity reaction and interruptions in therapy. AIDS (2001) 0.81
Spinal dural arteriovenous fistulas--presentation, management and outcome in a single neurosurgical institution. Br J Neurosurg (2012) 0.81
Bacteraemia in neonatal foals: clinicopathological differences between Gram-positive and Gram-negative infections, and single organism and mixed infections. Equine Vet J (2007) 0.81
One-step disposable chambers for sperm concentration and motility assessment: how do they compare with the World Health Organization's recommended methods? Hum Reprod (2001) 0.81
A rapid, large-scale method for purification of the metallo-carboxypeptidase inhibitor from potato tubers. Anal Biochem (1983) 0.81
Proteinase inhibitor-inducing activity of the prohormone prosystemin resides exclusively in the C-terminal systemin domain. Proc Natl Acad Sci U S A (1999) 0.80
The synthesis and enzymic hydrolysis of (E)-2-[2,3-2H2]propenyl glucosinolate: confirmation of the rearrangement of the thiohydroximate moiety. Phytochemistry (2007) 0.79
Different cup migration in rheumatoid arthritis and arthrosis: a radiographic analysis of 127 uncemented acetabular cups. Acta Orthop Scand (1998) 0.79
Personality and psychosocial function after brain injury. Brain Inj (1995) 0.79
Autoantibodies in Chagas' heart disease: possible markers of severe Chagas' heart complaint. Mem Inst Oswaldo Cruz (1992) 0.78
Proton NMR assignments of systemin. J Protein Chem (1992) 0.78